VitaSpring Biomedical Co. Ltd. Stock Other OTC
Equities
VSBC
US92851B1026
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 0.25 | Sales 2022 | 5.61 | Capitalization | 2.89B |
---|---|---|---|---|---|
Net income 2021 | - | Net income 2022 | 1M | EV / Sales 2021 | 2,936,169,226 x |
Net cash position 2021 | 45.4K | Net Debt 2022 | 356K | EV / Sales 2022 | 515,149,430 x |
P/E ratio 2021 |
-2,570
x | P/E ratio 2022 |
2,282
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 41.23% |
Managers | Title | Age | Since |
---|---|---|---|
Cheng Hsiang Kao
CEO | Chief Executive Officer | - | 20-01-20 |
Pao Chi Chu
CHM | Chairman | 70 | 20-01-20 |
Jer Li Lin
CTO | Chief Tech/Sci/R&D Officer | - | 20-01-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pao Chi Chu
CHM | Chairman | 70 | 20-01-20 |
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 107B | |
-2.59% | 21.6B | |
-12.38% | 22.31B | |
-5.29% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |